1
|
Luque R, Osborn HP, Leleu A, Pallé E, Bonfanti A, Barragán O, Wilson TG, Broeg C, Cameron AC, Lendl M, Maxted PFL, Alibert Y, Gandolfi D, Delisle JB, Hooton MJ, Egger JA, Nowak G, Lafarga M, Rapetti D, Twicken JD, Morales JC, Carleo I, Orell-Miquel J, Adibekyan V, Alonso R, Alqasim A, Amado PJ, Anderson DR, Anglada-Escudé G, Bandy T, Bárczy T, Barrado Navascues D, Barros SCC, Baumjohann W, Bayliss D, Bean JL, Beck M, Beck T, Benz W, Billot N, Bonfils X, Borsato L, Boyle AW, Brandeker A, Bryant EM, Cabrera J, Carrazco-Gaxiola S, Charbonneau D, Charnoz S, Ciardi DR, Cochran WD, Collins KA, Crossfield IJM, Csizmadia S, Cubillos PE, Dai F, Davies MB, Deeg HJ, Deleuil M, Deline A, Delrez L, Demangeon ODS, Demory BO, Ehrenreich D, Erikson A, Esparza-Borges E, Falk B, Fortier A, Fossati L, Fridlund M, Fukui A, Garcia-Mejia J, Gill S, Gillon M, Goffo E, Gómez Maqueo Chew Y, Güdel M, Guenther EW, Günther MN, Hatzes AP, Helling C, Hesse KM, Howell SB, Hoyer S, Ikuta K, Isaak KG, Jenkins JM, Kagetani T, Kiss LL, Kodama T, Korth J, Lam KWF, Laskar J, Latham DW, Lecavelier des Etangs A, Leon JPD, Livingston JH, Magrin D, Matson RA, Matthews EC, Mordasini C, Mori M, Moyano M, Munari M, Murgas F, Narita N, Nascimbeni V, Olofsson G, Osborne HLM, Ottensamer R, Pagano I, Parviainen H, Peter G, Piotto G, Pollacco D, Queloz D, Quinn SN, Quirrenbach A, Ragazzoni R, Rando N, Ratti F, Rauer H, Redfield S, Ribas I, Ricker GR, Rudat A, Sabin L, Salmon S, Santos NC, Scandariato G, Schanche N, Schlieder JE, Seager S, Ségransan D, Shporer A, Simon AE, Smith AMS, Sousa SG, Stalport M, Szabó GM, Thomas N, Tuson A, Udry S, Vanderburg AM, Van Eylen V, Van Grootel V, Venturini J, Walter I, Walton NA, Watanabe N, Winn JN, Zingales T. A resonant sextuplet of sub-Neptunes transiting the bright star HD 110067. Nature 2023; 623:932-937. [PMID: 38030780 DOI: 10.1038/s41586-023-06692-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Accepted: 09/28/2023] [Indexed: 12/01/2023]
Abstract
Planets with radii between that of the Earth and Neptune (hereafter referred to as 'sub-Neptunes') are found in close-in orbits around more than half of all Sun-like stars1,2. However, their composition, formation and evolution remain poorly understood3. The study of multiplanetary systems offers an opportunity to investigate the outcomes of planet formation and evolution while controlling for initial conditions and environment. Those in resonance (with their orbital periods related by a ratio of small integers) are particularly valuable because they imply a system architecture practically unchanged since its birth. Here we present the observations of six transiting planets around the bright nearby star HD 110067. We find that the planets follow a chain of resonant orbits. A dynamical study of the innermost planet triplet allowed the prediction and later confirmation of the orbits of the rest of the planets in the system. The six planets are found to be sub-Neptunes with radii ranging from 1.94R⊕ to 2.85R⊕. Three of the planets have measured masses, yielding low bulk densities that suggest the presence of large hydrogen-dominated atmospheres.
Collapse
Affiliation(s)
- R Luque
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, IL, USA.
| | - H P Osborn
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA
- Kavli Institute for Astrophysics and Space Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - A Leleu
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - E Pallé
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Departamento de Astrofisica, Universidad de La Laguna, La Laguna, Tenerife, Spain
| | - A Bonfanti
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - O Barragán
- Sub-department of Astrophysics, Department of Physics, University of Oxford, Oxford, UK
| | - T G Wilson
- Centre for Exoplanet Science, SUPA School of Physics and Astronomy, University of St Andrews, St Andrews, UK
- Department of Physics, University of Warwick, Coventry, UK
- Centre for Exoplanets and Habitability, University of Warwick, Coventry, UK
| | - C Broeg
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
- Center for Space and Habitability, University of Bern, Bern, Switzerland
| | - A Collier Cameron
- Centre for Exoplanet Science, SUPA School of Physics and Astronomy, University of St Andrews, St Andrews, UK
| | - M Lendl
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - P F L Maxted
- Astrophysics Group, Lennard Jones Building, Keele University, Keele, UK
| | - Y Alibert
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
- Center for Space and Habitability, University of Bern, Bern, Switzerland
| | - D Gandolfi
- Dipartimento di Fisica, Universita degli Studi di Torino, Torino, Italy
| | - J-B Delisle
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - M J Hooton
- Cavendish Laboratory, University of Cambridge, Cambridge, UK
| | - J A Egger
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
| | - G Nowak
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Departamento de Astrofisica, Universidad de La Laguna, La Laguna, Tenerife, Spain
- Institute of Astronomy, Faculty of Physics, Astronomy and Informatics, Nicolaus Copernicus University, Toruń, Poland
| | - M Lafarga
- Department of Physics, University of Warwick, Coventry, UK
- Centre for Exoplanets and Habitability, University of Warwick, Coventry, UK
| | - D Rapetti
- NASA Ames Research Center, Moffett Field, CA, USA
- Research Institute for Advanced Computer Science, Universities Space Research Association, Washington, DC, USA
| | - J D Twicken
- NASA Ames Research Center, Moffett Field, CA, USA
- SETI Institute, Mountain View, CA, USA
| | - J C Morales
- Institut de Ciencies de l'Espai (ICE-CSIC), Bellaterra, Spain
- Institut d'Estudis Espacials de Catalunya (IEEC), Barcelona, Spain
| | - I Carleo
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- INAF - Osservatorio Astrofisico di Torino, Pino Torinese, Italy
| | - J Orell-Miquel
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Departamento de Astrofisica, Universidad de La Laguna, La Laguna, Tenerife, Spain
| | - V Adibekyan
- Instituto de Astrofísica e Ciências do Espaço, Universidade do Porto, Porto, Portugal
- Departamento de Física e Astronomia, Faculdade de Ciências, Universidade do Porto, Porto, Portugal
| | - R Alonso
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Departamento de Astrofisica, Universidad de La Laguna, La Laguna, Tenerife, Spain
| | - A Alqasim
- Mullard Space Science Laboratory, University College London, Dorking, UK
| | - P J Amado
- Instituto de Astrofísica de Andalucía (IAA-CSIC), Granada, Spain
| | - D R Anderson
- Department of Physics, University of Warwick, Coventry, UK
- Centre for Exoplanets and Habitability, University of Warwick, Coventry, UK
| | - G Anglada-Escudé
- Institut de Ciencies de l'Espai (ICE-CSIC), Bellaterra, Spain
- Institut d'Estudis Espacials de Catalunya (IEEC), Barcelona, Spain
| | - T Bandy
- European Space Research and Technology Centre (ESTEC), European Space Agency (ESA), Noordwijk, The Netherlands
| | | | | | - S C C Barros
- Instituto de Astrofisica e Ciencias do Espaco, Universidade do Porto, Porto, Portugal
- Departamento de Fisica e Astronomia, Faculdade de Ciencias, Universidade do Porto, Porto, Portugal
| | - W Baumjohann
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - D Bayliss
- Department of Physics, University of Warwick, Coventry, UK
| | - J L Bean
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, IL, USA
| | - M Beck
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - T Beck
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
| | - W Benz
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
- Center for Space and Habitability, University of Bern, Bern, Switzerland
| | - N Billot
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - X Bonfils
- Université Grenoble Alpes, CNRS, IPAG, Grenoble, France
| | - L Borsato
- INAF - Osservatorio Astronomico di Padova, Padova, Italy
| | - A W Boyle
- Department of Astronomy, California Institute of Technology, Pasadena, CA, USA
| | - A Brandeker
- Department of Astronomy, Stockholm University, AlbaNova University Center, Stockholm, Sweden
| | - E M Bryant
- Department of Physics, University of Warwick, Coventry, UK
- Mullard Space Science Laboratory, University College London, Dorking, UK
| | - J Cabrera
- Institute of Planetary Research, German Aerospace Center (DLR), Berlin, Germany
| | - S Carrazco-Gaxiola
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de México, Mexico
- Department of Physics and Astronomy, Georgia State University, Atlanta, GA, USA
- RECONS Institute, Chambersburg, PA, USA
| | - D Charbonneau
- Center for Astrophysics | Harvard & Smithsonian, Cambridge, MA, USA
| | - S Charnoz
- Université de Paris Cité, Institut de Physique du Globe de Paris, CNRS, Paris, France
| | - D R Ciardi
- Department of Astronomy, California Institute of Technology, Pasadena, CA, USA
| | - W D Cochran
- McDonald Observatory, The University of Texas, Austin, TX, USA
- Center for Planetary Systems Habitability, The University of Texas, Austin, TX, USA
| | - K A Collins
- Center for Astrophysics | Harvard & Smithsonian, Cambridge, MA, USA
| | - I J M Crossfield
- Department of Physics and Astronomy, University of Kansas, Lawrence, KS, USA
| | - Sz Csizmadia
- Institute of Planetary Research, German Aerospace Center (DLR), Berlin, Germany
| | - P E Cubillos
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
- INAF - Osservatorio Astrofisico di Torino, Pino Torinese, Italy
| | - F Dai
- Department of Astronomy, California Institute of Technology, Pasadena, CA, USA
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA, USA
| | - M B Davies
- Centre for Mathematical Sciences, Lund University, Lund, Sweden
| | - H J Deeg
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Departamento de Astrofisica, Universidad de La Laguna, La Laguna, Tenerife, Spain
| | - M Deleuil
- Aix Marseille Univ., CNRS, CNES, LAM, Marseille, France
| | - A Deline
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - L Delrez
- Astrobiology Research Unit, Université de Liège, Liège, Belgium
- Space sciences, Technologies and Astrophysics Research (STAR) Institute, Université de Liège, Liège, Belgium
| | - O D S Demangeon
- Instituto de Astrofisica e Ciencias do Espaco, Universidade do Porto, Porto, Portugal
- Departamento de Fisica e Astronomia, Faculdade de Ciencias, Universidade do Porto, Porto, Portugal
| | - B-O Demory
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
- Center for Space and Habitability, University of Bern, Bern, Switzerland
| | - D Ehrenreich
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
- Centre Vie dans l'Univers, Faculté des sciences, Université de Genève, Genève 4, Switzerland
| | - A Erikson
- Institute of Planetary Research, German Aerospace Center (DLR), Berlin, Germany
| | - E Esparza-Borges
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Departamento de Astrofisica, Universidad de La Laguna, La Laguna, Tenerife, Spain
| | - B Falk
- Space Telescope Science Institute, Baltimore, MD, USA
| | - A Fortier
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
- Center for Space and Habitability, University of Bern, Bern, Switzerland
| | - L Fossati
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - M Fridlund
- Leiden Observatory, University of Leiden, Leiden, The Netherlands
- Onsala Space Observatory, Department of Space, Earth and Environment, Chalmers University of Technology, Onsala, Sweden
| | - A Fukui
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Komaba Institute for Science, The University of Tokyo, Tokyo, Japan
| | - J Garcia-Mejia
- Center for Astrophysics | Harvard & Smithsonian, Cambridge, MA, USA
| | - S Gill
- Department of Physics, University of Warwick, Coventry, UK
| | - M Gillon
- Astrobiology Research Unit, Université de Liège, Liège, Belgium
| | - E Goffo
- Dipartimento di Fisica, Universita degli Studi di Torino, Torino, Italy
- Thüringer Landessternwarte Tautenburg, Tautenburg, Germany
| | - Y Gómez Maqueo Chew
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de México, Mexico
| | - M Güdel
- Department of Astrophysics, University of Vienna, Vienna, Austria
| | - E W Guenther
- Thüringer Landessternwarte Tautenburg, Tautenburg, Germany
| | - M N Günther
- European Space Research and Technology Centre (ESTEC), European Space Agency (ESA), Noordwijk, The Netherlands
| | - A P Hatzes
- Thüringer Landessternwarte Tautenburg, Tautenburg, Germany
| | - Ch Helling
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - K M Hesse
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA
- Kavli Institute for Astrophysics and Space Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - S B Howell
- NASA Ames Research Center, Moffett Field, CA, USA
| | - S Hoyer
- Aix Marseille Univ., CNRS, CNES, LAM, Marseille, France
| | - K Ikuta
- Department of Multi-Disciplinary Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan
| | - K G Isaak
- European Space Research and Technology Centre (ESTEC), European Space Agency (ESA), Noordwijk, The Netherlands
| | - J M Jenkins
- NASA Ames Research Center, Moffett Field, CA, USA
| | - T Kagetani
- Department of Multi-Disciplinary Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan
| | - L L Kiss
- Konkoly Observatory, HUN-REN Research Centre for Astronomy and Earth Sciences, Budapest, Hungary
- Institute of Physics, ELTE Eötvös Loránd University, Budapest, Hungary
| | - T Kodama
- Komaba Institute for Science, The University of Tokyo, Tokyo, Japan
| | - J Korth
- Lund Observatory, Division of Astrophysics, Department of Physics, Lund University, Lund, Sweden
| | - K W F Lam
- Institute of Planetary Research, German Aerospace Center (DLR), Berlin, Germany
| | - J Laskar
- IMCCE, UMR8028 CNRS, Observatoire de Paris, PSL Univ., Sorbonne Univ., Paris, France
| | - D W Latham
- Center for Astrophysics | Harvard & Smithsonian, Cambridge, MA, USA
| | - A Lecavelier des Etangs
- Institut d'Astrophysique de Paris, UMR7095 CNRS, Université Pierre & Marie Curie, Paris, France
| | - J P D Leon
- Department of Multi-Disciplinary Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan
| | - J H Livingston
- Astrobiology Center, Tokyo, Japan
- National Astronomical Observatory of Japan, Tokyo, Japan
- Department of Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Tokyo, Japan
| | - D Magrin
- INAF - Osservatorio Astronomico di Padova, Padova, Italy
| | - R A Matson
- United States Naval Observatory, Washington, DC, USA
| | - E C Matthews
- Max Planck Institute for Astronomy, Heidelberg, Germany
| | - C Mordasini
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
- Center for Space and Habitability, University of Bern, Bern, Switzerland
| | - M Mori
- Department of Multi-Disciplinary Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan
| | - M Moyano
- Instituto de Astronomía, Universidad Católica del Norte, Antofagasta, Chile
| | - M Munari
- INAF - Osservatorio Astrofisico di Catania, Catania, Italy
| | - F Murgas
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Departamento de Astrofisica, Universidad de La Laguna, La Laguna, Tenerife, Spain
| | - N Narita
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Komaba Institute for Science, The University of Tokyo, Tokyo, Japan
- Astrobiology Center, Tokyo, Japan
| | - V Nascimbeni
- INAF - Osservatorio Astronomico di Padova, Padova, Italy
| | - G Olofsson
- Department of Astronomy, Stockholm University, AlbaNova University Center, Stockholm, Sweden
| | - H L M Osborne
- Mullard Space Science Laboratory, University College London, Dorking, UK
| | - R Ottensamer
- Department of Astrophysics, University of Vienna, Vienna, Austria
| | - I Pagano
- INAF - Osservatorio Astrofisico di Catania, Catania, Italy
| | - H Parviainen
- Instituto de Astrofisica de Canarias, La Laguna, Tenerife, Spain
- Departamento de Astrofisica, Universidad de La Laguna, La Laguna, Tenerife, Spain
| | - G Peter
- Institute of Optical Sensor Systems, German Aerospace Center (DLR), Berlin, Germany
| | - G Piotto
- INAF - Osservatorio Astronomico di Padova, Padova, Italy
- Dipartimento di Fisica e Astronomia "Galileo Galilei", Universita degli Studi di Padova, Padova, Italy
| | - D Pollacco
- Department of Physics, University of Warwick, Coventry, UK
| | - D Queloz
- Cavendish Laboratory, University of Cambridge, Cambridge, UK
- Department of Physics, ETH Zurich, Zurich, Switzerland
| | - S N Quinn
- Center for Astrophysics | Harvard & Smithsonian, Cambridge, MA, USA
| | - A Quirrenbach
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, Heidelberg, Germany
| | - R Ragazzoni
- INAF - Osservatorio Astronomico di Padova, Padova, Italy
- Dipartimento di Fisica e Astronomia "Galileo Galilei", Universita degli Studi di Padova, Padova, Italy
| | - N Rando
- European Space Research and Technology Centre (ESTEC), European Space Agency (ESA), Noordwijk, The Netherlands
| | - F Ratti
- European Space Research and Technology Centre (ESTEC), European Space Agency (ESA), Noordwijk, The Netherlands
| | - H Rauer
- Institute of Planetary Research, German Aerospace Center (DLR), Berlin, Germany
- Zentrum für Astronomie und Astrophysik, Technische Universität Berlin, Berlin, Germany
- Institut für Geologische Wissenschaften, Freie Universität Berlin, Berlin, Germany
| | - S Redfield
- Astronomy Department, Wesleyan University, Middletown, CT, USA
- Van Vleck Observatory, Wesleyan University, Middletown, CT, USA
| | - I Ribas
- Institut de Ciencies de l'Espai (ICE-CSIC), Bellaterra, Spain
- Institut d'Estudis Espacials de Catalunya (IEEC), Barcelona, Spain
| | - G R Ricker
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA
- Kavli Institute for Astrophysics and Space Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - A Rudat
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA
- Kavli Institute for Astrophysics and Space Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - L Sabin
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ensenada, Mexico
| | - S Salmon
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - N C Santos
- Instituto de Astrofisica e Ciencias do Espaco, Universidade do Porto, Porto, Portugal
- Departamento de Fisica e Astronomia, Faculdade de Ciencias, Universidade do Porto, Porto, Portugal
| | - G Scandariato
- INAF - Osservatorio Astrofisico di Catania, Catania, Italy
| | - N Schanche
- Center for Space and Habitability, University of Bern, Bern, Switzerland
- Department of Astronomy, University of Maryland, College Park, MD, USA
| | - J E Schlieder
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - S Seager
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA
- Kavli Institute for Astrophysics and Space Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA
- Department of Aeronautics and Astronautics, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - D Ségransan
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - A Shporer
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA
- Kavli Institute for Astrophysics and Space Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - A E Simon
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
| | - A M S Smith
- Institute of Planetary Research, German Aerospace Center (DLR), Berlin, Germany
| | - S G Sousa
- Instituto de Astrofisica e Ciencias do Espaco, Universidade do Porto, Porto, Portugal
| | - M Stalport
- Space sciences, Technologies and Astrophysics Research (STAR) Institute, Université de Liège, Liège, Belgium
| | - Gy M Szabó
- Gothard Astrophysical Observatory, ELTE Eötvös Loránd University, Szombathely, Hungary
- HUN-REN-ELTE Exoplanet Research Group, Szombathely, Hungary
| | - N Thomas
- Space Research and Planetary Sciences, Physics Institute, University of Bern, Bern, Switzerland
| | - A Tuson
- Cavendish Laboratory, University of Cambridge, Cambridge, UK
| | - S Udry
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - A M Vanderburg
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA
- Kavli Institute for Astrophysics and Space Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - V Van Eylen
- Mullard Space Science Laboratory, University College London, Dorking, UK
| | - V Van Grootel
- Space sciences, Technologies and Astrophysics Research (STAR) Institute, Université de Liège, Liège, Belgium
| | - J Venturini
- Observatoire Astronomique de l'Université de Genève, Versoix, Switzerland
| | - I Walter
- Institute of Optical Sensor Systems, German Aerospace Center (DLR), Berlin, Germany
| | - N A Walton
- Institute of Astronomy, University of Cambridge, Cambridge, UK
| | - N Watanabe
- Department of Multi-Disciplinary Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan
| | - J N Winn
- Department of Astrophysical Sciences, Princeton University, Princeton, NJ, USA
| | - T Zingales
- Dipartimento di Fisica e Astronomia "Galileo Galilei", Universita degli Studi di Padova, Padova, Italy
| |
Collapse
|
2
|
Shlomi D, Beck T, Reuveny R, Segel MJ. Prediction of exercise respiratory limitation from pulmonary function tests. Pulmonology 2023:S2531-0437(23)00001-6. [PMID: 36717291 DOI: 10.1016/j.pulmoe.2022.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2022] [Revised: 12/11/2022] [Accepted: 12/22/2022] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND Evaluation of unexplained exercise intolerance is best resolved by cardiopulmonary exercise testing (CPET) which enables the determination of the exercise limiting system in most cases. Traditionally, pulmonary function tests (PFTs) at rest are not used for the prediction of a respiratory limitation on CPET. OBJECTIVE We sought cut-off values on PFTs that might, a priori, rule-in or rule-out a respiratory limitation in CPET. METHODS Patients who underwent CPET in our institute were divided into two groups according to spirometry: obstructive and non-obstructive. Each group was randomly divided 2:1 into derivation and validation cohorts respectively. We analyzed selected PFTs parameters in the derivation groups in order to establish maximal and minimal cut-off values for which a respiratory limitation could be ruled-in or ruled-out. We then validated these values in the validation cohorts. RESULTS Of 593 patients who underwent a CPET, 126 were in the obstructive and 467 in the non-obstructive group. In patients with obstructive lung disease, forced expiratory volume in 1 second (FEV1) ≥ 61% predicted could rule out a respiratory limitation, while FEV1 ≤ 33% predicted was always associated with a respiratory limitation. For patients with non-obstructive spirometry, FEV1 of ≥ 73% predicted could rule-out a respiratory limitation. Application of this algorithm might have saved up to 47% and 71% of CPETs in our obstructive and non-obstructive groups, respectively. CONCLUSION Presence or absence of a respiratory limitation on CPET can be predicted in some cases based on a PFTs performed at rest.
Collapse
Affiliation(s)
- D Shlomi
- Adelson School of Medicine, Ariel University, Ariel, Israel; Pulmonary Clinic, Dan-Petah-Tiqwa District, Clalit Health Services - Community Division, Ramat-Gan, Israel.
| | - T Beck
- Department of Surgical Oncology (Surgery C), Sheba Medical Center, Tel-HaShomer, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - R Reuveny
- Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Pulmonary Institute, Sheba Medical Center, Tel-HaShomer, Ramat Gan, Israel; Physical Therapy Department, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel
| | - M J Segel
- Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Pulmonary Institute, Sheba Medical Center, Tel-HaShomer, Ramat Gan, Israel
| |
Collapse
|
3
|
Gettinger S, Schenker M, De Langen J, Fischer J, Morgensztern D, Ciuleanu TE, Beck T, De Castro Carpeno J, Schumann C, Yang X, Telivala B, Deschepper K, Nadal E, Schalper K, Spires T, Balli D, Nassar A, Karam S, Bhingare A, Spigel D. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
4
|
Cherny NI, Parrinello CM, Kwiatkowsky L, Hunnicutt J, Beck T, Schaefer E, Thurow T, Kolodziej M. Feasibility of Large-Scale Implementation of an Electronic Patient-Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncol Pract 2022; 18:e1918-e1926. [PMID: 36240475 PMCID: PMC9750604 DOI: 10.1200/op.22.00180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE The use of digital symptom monitoring with patient-reported outcomes (PROs) has been shown to improve patient outcomes. The evidence of benefit has been largely derived from research studies. The feasibility of adopting this technology in the real-world setting is unknown. METHODS We report on the clinical implementation of a proprietary electronic patient-reported outcome (ePRO)-based digital symptom monitoring platform at the Highlands Oncology Group practice, a large community oncology practice. We present here our experience with patient enrollment, engagement, and retention; reasons for discontinued use; proportion of reports generating alerts and containing severe symptoms; and the responses to alerts including nursing telephone consultations and urgent office visits. RESULTS Over an approximately 17-month period, 923 patients were successfully enrolled. Patients enrolled from June 20, 2020, through November 30, 2021, with follow-up through February 28, 2022. Retention rates at 3, 6, 9, and 12 months were 94%, 88%, 73%, and 67%, respectively, with greater retention at 12 months in patients age 65 years or older. Few patients discontinued use for reasons related to the platform (n = 47; 5%). Of the 25,311 ePRO reports submitted, 49% (n = 12,334) exceeded the predefined alert thresholds and 8% (n = 1,920) included severe symptoms. The nursing team responded within 24 hours by telephone to 31.2% (n = 3,910) of all reports with alerts. Of reports with severe symptoms, 72.7% (n = 1,395) received a call. Only 6.4% (n = 249) of phone calls required an office evaluation within 72 hours of the report. CONCLUSION This single-center experience indicates that an ePRO-based digital symptom monitoring platform can be effectively implemented at a large scale with a high level of long-term patient engagement. Most reports could be effectively resolved by nurses, and physician intervention was infrequently required.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Michael Kolodziej
- Canopy, New York, New York,Michael Kolodziej, MD, 166 Kaydeross Park Rd, Saratoga Springs, NY 12866-8704; e-mail:
| |
Collapse
|
5
|
Ellis ET, Bauer MA, Beck T, Bradford DS, Thompson J, Kulik MC, Su JL. Abstract 2242: Impact of low-dose computed tomography screening for lung cancer at a community oncology clinic on stage of lung cancer diagnosis in the catchment area. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Arkansas has the second-highest incidence of lung cancer in the U.S., with a largely rural and medically underserved population. Low-dose computed tomography (LDCT) is a well-established procedure for lung cancer screening in academic medical centers, but few local community oncology centers utilize this technology. Highlands Oncology Group (HOG), located in Northwest Arkansas (NWA), took the initiative to bring LDCT screening to a non-academic medical center and provide routine LDCT screening to a rural population. The objective of this study is to evaluate the benefits of free LDCT screening at a community oncology clinic.
Methods: The study compared for-fee and free periods of LDCT screening at HOG and their impact on identifying cancer in NWA. The study population was patients in HOG’s catchment area who fell into the risk categories set by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology to be eligible for screening between March 2013 and February 2020.
Results: A total of 5,402 eligible participants enrolled in the study. During ten months of for-fee screening (n=60), 3.3% of patients diagnosed had Stage I lung cancer, and 1.7% were diagnosed with Stages II-IV. During the first ten months of free screening (n=729), 3% of patients were diagnosed with Stage I lung cancer, 1.8% were diagnosed with Stages II-IV, and 1.1% were diagnosed with other cancers. Over the entire program until February 2020 (n=5,402), a total of 76 patients were diagnosed with Stage I lung cancer, 52 were diagnosed with Stage II-IV, and 35 were diagnosed with other cancers.
Conclusion: The result of this study suggests that eligible patients are more receptive to free lung cancer screening, even though most insurance coverage does not have a required co-pay for eligible patients. We also observed an increased diagnosis rate for early-stage lung cancers due to increased patient influx with free LDCT screening. The state central registry data showed a decline in distant lung cancer after the free LDCT screening offered in the northwestern counties in the HOG catchment area. At the same time, no such trend is visible for the entire state, suggesting a stage shift in lung cancer due to free LDCT screening.
Citation Format: Edgar T. Ellis, Michael A. Bauer, Thaddeus Beck, Daniel S. Bradford, Joanna Thompson, Margarete C. Kulik, Joseph L. Su. Impact of low-dose computed tomography screening for lung cancer at a community oncology clinic on stage of lung cancer diagnosis in the catchment area [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2242.
Collapse
Affiliation(s)
- Edgar T. Ellis
- 1University of Arkansas for Medical Sciences, Little Rock, AR
| | | | | | | | | | | | - Joseph L. Su
- 1University of Arkansas for Medical Sciences, Little Rock, AR
| |
Collapse
|
6
|
Makhoul I, Ibrahim SM, Abu-Rmaileh M, Jousheghany F, Siegel E, Rogers LJ, Lee JJ, Pina-Oviedo S, Post GR, Beck T, Kieber-Emmons T, Monzavi-Karbassi B. Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p2-14-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: We have developed P10s-PADRE, a carbohydrate-mimetic-based peptide, cancer vaccine and demonstrated its safety and immunogenicity in a Phase I clinical trial performed in stage IV breast cancer patients. HR+/HER2- breast cancer is the most common form of breast cancer diagnosed in the United States. These patients face a persistent risk of distant recurrence long after completion of their treatment and new strategies to activate anti-tumor immune responses can improve outcomes of standard therapies. The current study was performed to examine the feasibility, safety and immunogenicity of adding P10s-PADRE to standard-of-care chemotherapy in HR+/HER2− early-stage breast cancer patients. Methods: Five combination schedules were designed based on the timing of immunizations relative to a standard-of-care neoadjuvant chemotherapy regimen. Induction of on-treatment antibody and cellular responses, including T-cells, natural killer (NK) cells, and cytokines was determined. Tumor-infiltrating lymphocytes were quantified in core and surgical biopsies. The data were used to define the treatment effect in general and the vaccine contribution in particular. Results: Combination of P10s-PADRE with chemotherapy was safe and immunogenic. Antibody response was superior in a particular combination schedule, called schedule C, where 3 weekly immunizations preceded the first dose of chemotherapy. We observed that the schedule C, relative to other schedules, displayed an increase in CD16 expression on NK cells, a drop in serum IFN-γ, and an increase in quantity of stromal TILs in residual tumors. Subjects demonstrated a significant reduction in the size of their primary tumor and three subjects achieved pCR. Conclusions: The timing of the immunization relative to the chemotherapy seems to define the type and strength of the immune responses elicited. A particular combination schedule, schedule C, appears promising and the results warrant the conduct of randomized phase II trials.
Citation Format: Issam Makhoul, Saddam M Ibrahim, Muhammad Abu-Rmaileh, Fariba Jousheghany, Eric Siegel, Lora J Rogers, John J Lee, Sergio Pina-Oviedo, Ginell R Post, Thaddeus Beck, Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi. Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-14-15.
Collapse
Affiliation(s)
- Issam Makhoul
- University of Arkansas for Medical Sciences, Little Rock, AR
| | | | | | | | - Eric Siegel
- University of Arkansas for Medical Sciences, Little Rock, AR
| | - Lora J Rogers
- University of Arkansas for Medical Sciences, Little Rock, AR
| | - John J Lee
- University of Arkansas for Medical Sciences, Little Rock, AR
| | | | - Ginell R Post
- University of Arkansas for Medical Sciences, Little Rock, AR
| | - Thaddeus Beck
- University of Arkansas for Medical Sciences, Little Rock, AR
| | | | | |
Collapse
|
7
|
Beck T, Sloane AJ, Carola DL, McElwee D, Edwards C, Bell-Carey B, Leopold K, Greenspan JS, Aghai ZH. Management of well appearing infants born to afebrile mothers with inadequate GBS prophylaxis: A retrospective comparison of the three approaches recommended by the COFN. J Neonatal Perinatal Med 2021; 15:297-302. [PMID: 34806622 DOI: 10.3233/npm-210798] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND There are three different approaches set forth by the Committee on the Fetus and Newborn (COFN) for managing asymptomatic neonates born to mothers with inadequate intrapartum antibiotic prophylaxis (IAP) for early-onset Group B Strep (GBS) infection. The first approach is that of categorical risk factor assessments, and recommends that asymptomatic infants born to afebrile mothers with inadequate IAP for GBS be monitored with clinical observation for 36-48 hours. The second approach recommends serial physical examinations and vital signs for 36-48 hours to closely monitor changes in clinical condition for all patients. The Kaiser Permanente EOS risk calculator (SRC) is an example of the third approach, a multivariate risk assessment, and it takes into consideration several perinatal risk factors. This multivariate risk assessment then provides recommendations for reassessment and management based on presume risk of the infant developing or having Early Onset Sepsis (EOS). The aim of our study was to compare these three recently published recommendations from the COFN for the management of asymptomatic neonates born to afebrile mothers with inadequate IAP for GBS. STUDY DESIGN This is a retrospective study of asymptomatic neonates with gestational age ≥35 weeks born to afebrile mothers with indicated inadequate IAP for GBS between April 2017 and July 2020. Management recommendations of the SRC were compared to the recommendations of categorical risk assessment and risk assessment based on clinical condition. RESULTS A total of 7,396 infants were born during the study period, 394 (5.3%. to mothers with inadequate IAP. Recommendations for these infants according to both the categorical risk factor guideline and the clinical condition guideline include extended, close observation. However, the SRC recommended routine newborn care for 99.7%.f these infants. None of the infants developed EOS. CONCLUSION The SRC recommend routine neonatal care without enhanced and prolonged observation for nearly all asymptomatic infants born to afebrile mothers with inadequate IAP. As none of the infants in this cohort had EOS, further studies in a larger cohort are needed to establish the safety of SRC in neonates born to mothers with inadequate IAP.
Collapse
Affiliation(s)
- T Beck
- Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, PA, United States
| | - A J Sloane
- Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, PA, United States
| | - D L Carola
- Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, PA, United States
| | - D McElwee
- Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, PA, United States
| | - C Edwards
- Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, PA, United States
| | - B Bell-Carey
- Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, PA, United States
| | - K Leopold
- Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, PA, United States
| | - J S Greenspan
- Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, PA, United States
| | - Z H Aghai
- Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, PA, United States
| |
Collapse
|
8
|
Friman-Gayer U, Romig C, Hüther T, Albe K, Bacca S, Beck T, Berger M, Birkhan J, Hebeler K, Hernandez OJ, Isaak J, König S, Pietralla N, Ries PC, Rohrer J, Roth R, Savran D, Scheck M, Schwenk A, Seutin R, Werner V. Role of Chiral Two-Body Currents in ^{6}Li Magnetic Properties in Light of a New Precision Measurement with the Relative Self-Absorption Technique. Phys Rev Lett 2021; 126:102501. [PMID: 33784121 DOI: 10.1103/physrevlett.126.102501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 01/08/2021] [Accepted: 01/22/2021] [Indexed: 06/12/2023]
Abstract
A direct measurement of the decay width of the excited 0_{1}^{+} state of ^{6}Li using the relative self-absorption technique is reported. Our value of Γ_{γ,0_{1}^{+}→1_{1}^{+}}=8.17(14)_{stat.}(11)_{syst.} eV provides sufficiently low experimental uncertainties to test modern theories of nuclear forces. The corresponding transition rate is compared to the results of ab initio calculations based on chiral effective field theory that take into account contributions to the magnetic dipole operator beyond leading order. This enables a precision test of the impact of two-body currents that enter at next-to-leading order.
Collapse
Affiliation(s)
- U Friman-Gayer
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- Department of Physics and Astronomy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
- Triangle Universities Nuclear Laboratory, Duke University, Durham, North Carolina 27708, USA
| | - C Romig
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - T Hüther
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - K Albe
- Institut für Materialwissenschaft, Technische Universität Darmstadt, 64287 Darmstadt, Germany
| | - S Bacca
- Institut für Kernphysik and PRISMA Cluster of Excellence, Johannes Gutenberg-Universität Mainz, 55128 Mainz, Germany
- Helmholtz Institute Mainz, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64289 Darmstadt, Germany
| | - T Beck
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - M Berger
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - J Birkhan
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - K Hebeler
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64289 Darmstadt, Germany
| | - O J Hernandez
- Institut für Kernphysik and PRISMA Cluster of Excellence, Johannes Gutenberg-Universität Mainz, 55128 Mainz, Germany
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - J Isaak
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - S König
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64289 Darmstadt, Germany
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | - N Pietralla
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - P C Ries
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - J Rohrer
- Institut für Materialwissenschaft, Technische Universität Darmstadt, 64287 Darmstadt, Germany
| | - R Roth
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - D Savran
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64289 Darmstadt, Germany
| | - M Scheck
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- School of Engineering, University of the West of Scotland, Paisley, PA1 2BE, United Kingdom
- SUPA, Scottish Universities Physics Alliance, Glasgow, G12 8QQ, United Kingdom
| | - A Schwenk
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64289 Darmstadt, Germany
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Seutin
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64289 Darmstadt, Germany
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - V Werner
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| |
Collapse
|
9
|
Beck T, Richards D, Agajanian R, Berz D, Chen H, Ikpeazu C, Tarruella M, Verhoeven D, Pritchett Y, Malik R, Antal J, Hussein M. MO01.40 Trilaciclib has Myelopreservation Benefits in Patients with Small Cell Lung Cancer Treated with Chemotherapy, Irrespective of Age. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Beck T, Werner V, Pietralla N, Bhike M, Cooper N, Friman-Gayer U, Isaak J, Jolos RV, Kleemann J, Papst O, Tornow W, Bernards C, Crider BP, Ilieva RS, Löher B, Mihai C, Naqvi F, Pascu S, Peters EE, Prados-Estevez FM, Ross TJ, Savran D, Vanhoy JR, Zilges A. ΔK=0 M1 Excitation Strength of the Well-Deformed Nucleus ^{164}Dy from K Mixing. Phys Rev Lett 2020; 125:092501. [PMID: 32915599 DOI: 10.1103/physrevlett.125.092501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 07/30/2020] [Indexed: 06/11/2023]
Abstract
The size of a ΔK=0 M1 excitation strength has been determined for the first time in a predominantly axially deformed even-even nucleus. It has been obtained from the observation of a rare K-mixing situation between two close-lying J^{π}=1^{+} states of the nucleus ^{164}Dy with components characterized by intrinsic projection quantum numbers K=0 and K=1. Nuclear resonance fluorescence induced by quasimonochromatic linearly polarized γ-ray beams provided evidence for K mixing of the 1^{+} states at 3159.1(3) and 3173.6(3) keV in excitation energy from their γ-decay branching ratios into the ground-state band. The ΔK=0 transition strength of B(M1;0_{1}^{+}→1_{K=0}^{+})=0.008(1)μ_{N}^{2} was inferred from a mixing analysis of their M1 transition rates into the ground-state band. It is in agreement with predictions from the quasiparticle phonon nuclear model. This determination represents first experimental information on the M1 excitation strength of a nuclear quantum state with a negative R-symmetry quantum number.
Collapse
Affiliation(s)
- T Beck
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - V Werner
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- Wright Nuclear Structure Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - N Pietralla
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - M Bhike
- Department of Physics, Duke University and Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708-0308, USA
| | - N Cooper
- Wright Nuclear Structure Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - U Friman-Gayer
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - J Isaak
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - R V Jolos
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
- Department of Nuclear Physics, Dubna State University, 141980 Dubna, Russia
| | - J Kleemann
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - O Papst
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - W Tornow
- Department of Physics, Duke University and Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708-0308, USA
| | - C Bernards
- Wright Nuclear Structure Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - B P Crider
- Department of Physics and Astronomy, University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - R S Ilieva
- Wright Nuclear Structure Laboratory, Yale University, New Haven, Connecticut 06520, USA
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - B Löher
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - C Mihai
- Horia Hulubei National Institute of Physics and Nuclear Engineering, P.O. Box MG-6, R-76900 Bucharest, Romania
| | - F Naqvi
- Wright Nuclear Structure Laboratory, Yale University, New Haven, Connecticut 06520, USA
| | - S Pascu
- Horia Hulubei National Institute of Physics and Nuclear Engineering, P.O. Box MG-6, R-76900 Bucharest, Romania
| | - E E Peters
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - F M Prados-Estevez
- Department of Physics and Astronomy, University of Kentucky, Lexington, Kentucky 40506-0055, USA
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - T J Ross
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - D Savran
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - J R Vanhoy
- Department of Physics, United States Naval Academy, Annapolis, Maryland 21402-5026, USA
| | - A Zilges
- Institut für Kernphysik, Universität zu Köln, 50937 Köln, Germany
| |
Collapse
|
11
|
Steuer NB, Hugenroth K, Beck T, Spillner J, Kopp R, Reinartz S, Schmitz-Rode T, Steinseifer U, Wagner G, Arens J. Long-Term Venovenous Connection for Extracorporeal Carbon Dioxide Removal (ECCO 2R)-Numerical Investigation of the Connection to the Common Iliac Veins. Cardiovasc Eng Technol 2020; 11:362-380. [PMID: 32405926 PMCID: PMC7385029 DOI: 10.1007/s13239-020-00466-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 05/02/2020] [Indexed: 02/06/2023]
Abstract
Purpose Currently used cannulae for extracorporeal carbon dioxide removal (ECCO2R) are associated with complications such as thrombosis and distal limb ischemia, especially for long-term use. We hypothesize that the risk of these complications is reducible by attaching hemodynamically optimized grafts to the patient’s vessels. In this study, as a first step towards a long-term stable ECCO2R connection, we investigated the feasibility of a venovenous connection to the common iliac veins. To ensure its applicability, the drainage of reinfused blood (recirculation) and high wall shear stress (WSS) must be avoided. Methods A reference model was selected for computational fluid dynamics, on the basis of the analysis of imaging data. Initially, a sensitivity analysis regarding recirculation was conducted using as variables: blood flow, the distance of drainage and return to the iliocaval junction, as well as the diameter and position of the grafts. Subsequently, the connection was optimized regarding recirculation and the WSS was evaluated. We validated the simulations in a silicone model traversed by dyed fluid. Results The simulations were in good agreement with the validation measurements (mean deviation 1.64%). The recirculation ranged from 32.1 to 0%. The maximum WSS did not exceed 5.57 Pa. The position and diameter of the return graft show the highest influence on recirculation. A correlation was ascertained between recirculation and WSS. Overall, an inflow jet directed at a vessel wall entails not only high WSS, but also a flow separation and thereby an increased recirculation. Therefore, return grafts aligned to the vena cava are crucial. Conclusion In conclusion, a connection without recirculation could be feasible and therefore provides a promising option for a long-term ECCO2R connection.
Collapse
Affiliation(s)
- N B Steuer
- Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany.
| | - K Hugenroth
- Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - T Beck
- Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - J Spillner
- Clinic for Cardiothoracic Surgery, University Hospital RWTH Aachen, Aachen, Germany
| | - R Kopp
- Department of Anesthesiology, University Hospital RWTH Aachen, Aachen, Germany
| | - S Reinartz
- Department of Radiology, University Hospital RWTH Aachen, Aachen, Germany
| | - T Schmitz-Rode
- Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - U Steinseifer
- Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - G Wagner
- Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - J Arens
- Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany.,Chair in Engineering Organ Support Technologies, Department of Biomechanical Engineering, Faculty of Engineering Technologies, University of Twente, Enschede, The Netherlands
| |
Collapse
|
12
|
|
13
|
Shafique M, Fisher TL, Evans EE, Leonard JE, Pastore DR, Mallow C, Smith E, Zauderer M, Schröeder A, Chin K, Beck T, Baumgart M, Sanborn RE, Goldman JW. Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-ct086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Blockade of the PD/PD-L1 pathway is an effective immunotherapy for NSCLC, however rational combination therapies are needed to overcome resistance mechanisms. VX15/2503 (pepinemab) is an IgG4 humanized monoclonal antibody targeting semaphorin 4D (SEMA4D, CD100). In vivo preclinical models demonstrated antibody blockade of SEMA4D promoted immune infiltration and reduced function and recruitment of immunosuppressive myeloid cells within the tumor. Importantly, preclinical combinations of anti-SEMA4D with various immunotherapies enhanced T cell activity and tumor regression. Avelumab is a fully human IgG1 antibody specific for PD-L1 and has been approved for both Merkel cell and urothelial carcinomas. The CLASSICAL-Lung clinical trial tests the combination of pepinemab with avelumab to couple immune activation via checkpoint inhibition with beneficial modifications of the immune microenvironment via pepinemab. Here, we present interim results of the dose escalation portion of the CLASSICAL-Lung study.
Methods: This Phase Ib/II, open label, single arm, first-in-human combination study is designed to evaluate the safety, tolerability and efficacy of pepinemab in combination with avelumab in 62 subjects with advanced (IIIB/IV) NSCLC. The trial is split into dose escalation (n=12) and dose expansion (n=50) phases. The dose escalation portion includes patients who are immunotherapy naïve and have either progressed or declined standard first or second-line systemic anticancer therapy. The expansion phase includes a similar patient cohort as well as a second cohort of patients whose tumors progressed during or following immunotherapy. Patients in the dose escalation cohorts received ascending doses of pepinemab (5, 10, 20 mg/kg, Q2W) in combination with avelumab (10mg/kg, Q2W). The primary objective of dose escalation is safety, tolerability, and identification of the RP2D for dose expansion. Secondary objectives include evaluation of efficacy, immunogenicity, and PK/PD, and an exploratory objective is to identify candidate biomarkers of activity.
Results / Conclusions: Dose escalation was successfully completed. The combination was found to be well tolerated at all dose levels tested and the RP2D was selected as 10mg/kg pepinemab Q2W (with 10mg/kg avelumab Q2W) for the dose expansion phase. No concerning safety signals have been identified to date. The most frequent related AEs were grades 1 or 2 fatigue, pyrexia, or chills; no grade 3 AE occurred in more than one subject. One DLT, a grade 3 pulmonary embolism occurred in the 10mg/kg pepinemab cohort, resolved and did not recur in that same subject or additional subjects in any cohort. The disease control rate to date in all dose escalation patients treated for at least two months is 90%. More detailed data from the dose escalation cohorts will be presented, as well as an enrollment update for the dose expansion phase.
Clinical trial information: NCT03268057
Citation Format: Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest Smith, Maurice Zauderer, Andreas Schröeder, Kevin Chin, Thaddeus Beck, Megan Baumgart, Rachel E. Sanborn, Jonathan W. Goldman. Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT086.
Collapse
|
14
|
Laub G, Beck T, Golemis E. A NOVEL TRIBLOCK COPOLYMER HYDROGEL TALC FOAM DELIVERY SYSTEM TO TREAT MALIGNANT PLEURAL EFFUSIONS. Chest 2019. [DOI: 10.1016/j.chest.2019.02.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
15
|
Werner V, Witt W, Beck T, Pietralla N, Boromiza M, Clisu C, Costache C, Dinescu I, Ionescu A, John P, Koseoglou P, Margineăn N, Margineăn R, Mihai C, Mihai R, Mitu A, Negret A, Nita C, Olacel A, Pascu S, Serban A, Sotty C, Stan L, Suvaila R, Toma S, Turturica A, Ujeniuc S, Wiederhold J. Shape transitions between and within Zr isotopes. EPJ Web Conf 2019. [DOI: 10.1051/epjconf/201922301070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The Zirconium isotopes across the N=56,58 neutron subshell closures have been of special interest since years, sparked by the near doubly-magic features of 96Zr and the subsequent rapid onset of collectivity with a deformed ground-state structure already in 100Zr. Recent state-of-the-art shell model approaches did not only correctly describe this shape-phase transition in the Zr isotopic chain, but alsothe coexistence of non-collective structures and pronounced collectivity especially
in 96,98Zr. Theisotope 98Zr is located on the transition from spherical to deformed ground state structures. We summarize recent experimental work to obtain the B(E2) excitation strengths of the first 2+ state of98Zr, including a new experiment employing the recoil-distance Doppler-shift method following a two-neutron transfer reaction.
Collapse
|
16
|
Losch K, Schuff S, Balle F, Beck T, Redenbach C. A stochastic microstructure model for particle reinforced aluminium matrix composites. J Microsc 2018; 273:115-126. [PMID: 30444272 DOI: 10.1111/jmi.12766] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Accepted: 10/23/2018] [Indexed: 11/29/2022]
Abstract
Metal matrix composites are complex materials consisting of various phases which can display largely different mechanical properties. The deformation behaviour of these composites cannot be sufficiently modelled by averages or simple particle shapes due to the local stresses that occur on the particle edges. Therefore, a sophisticated model of the microstructure is needed. We introduce a method for stochastic modelling of a silicon carbide (SiC) particle reinforced aluminium matrix composite. The SiC particles are modelled by Laguerre polyhedra generated by densely packed spheres. The shape factors of the polyhedra have been fitted to the particle shapes observed in three-dimensional images. Particle elongation in extrusion direction and the observed log-normal volume distribution of the particles are included in the model by suitable scaling. An outlook is presented on how to model the grains of the polycrystalline aluminium matrix and intermetallic precipitates, which result from the strengthening mechanism of the matrix. LAY DESCRIPTION: Metal matrix composites are complex materials consisting of different phases which can display largely different mechanical properties. The deformation behaviour of these composites cannot be sufficiently modelled by averages or simple particle shapes due to the local stresses that occur on the particle edges. Therefore, a sophisticated model of the microstructure is needed. We introduce a method of stochastic modelling of a silicon carbide (SiC) particle reinforced aluminium matrix composite. The SiC particles are modelled by Laguerre polyhedra generated by densely packed spheres. The shape factors of the polyhedra have been fitted to the SiC shapes observed in three-dimensional images. Additionally, the polyhedra are scaled anisotropically to account for orientation anisotropy and to obtain a log-normal volume distribution. An outlook is presented on how to model the aluminium phase's grains and intermetallic precipitates, which result from the strengthening mechanism of the aluminium matrix alloy.
Collapse
Affiliation(s)
- K Losch
- Department of Mathematics, Technische Universität Kaiserslautern, Kaiserslautern, Germany
| | - S Schuff
- Institute of Materials Science and Engineering, Technische Universität Kaiserslautern, Kaiserslautern, Germany
| | - F Balle
- Institut für Nachhaltige Technische Systeme (INATECH), Albert-Ludwigs-Universität Freiburg, Freiburg, Germany
| | - T Beck
- Institute of Materials Science and Engineering, Technische Universität Kaiserslautern, Kaiserslautern, Germany
| | - C Redenbach
- Department of Mathematics, Technische Universität Kaiserslautern, Kaiserslautern, Germany
| |
Collapse
|
17
|
King K, Mayekar S, Beck T, Turian J, Marwaha G. Interfraction Tumor Volume Change is Associated with Locoregional Recurrence for NSCLC SBRT. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Bloom J, Borgia J, Blumenfeld P, Beck T, Marwaha G. Angiogenesis Biomarkers are Associated with Distant Metastasis Free Survival in Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy (SBRT). Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
Gettinger S, Beck T, Yang X, Telivala B, Morgensztern D, Velcheti V, Ramalingam S, Schalper K, Dajee M, Ranck A, Yang R, Spigel D. CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Beatty GL, Shahda S, Beck T, Uppal N, Cohen SJ, Donehower R, Gabayan AE, Assad A, Switzky J, Zhen H, Von Hoff DD. A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. Oncologist 2018; 24:14-e10. [PMID: 30115734 PMCID: PMC6324630 DOI: 10.1634/theoncologist.2017-0665] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Accepted: 06/18/2018] [Indexed: 01/05/2023] Open
Abstract
Lessons Learned. Itacitinib in combination with nab‐paclitaxel plus gemcitabine demonstrated an acceptable safety profile with clinical activity in patients with advanced solid tumors including pancreatic cancer. The results support future studies of itacitinib as a component of combination regimens with other immunologic and targeted small molecule anticancer agents.
Background. Cytokine‐mediated signaling via JAK/STAT is central to tumor growth, survival, and systemic inflammation, which is associated with cancer cachexia, particularly in pancreatic cancer. Because of their centrality in the pathogenesis of cancer cachexia and progression, JAK isozymes have emerged as promising therapeutic targets. Preclinical studies have demonstrated antiproliferative effects of JAK/STAT pathway inhibition in both in vitro and in vivo models of cancer, including pancreatic cancer. Methods. This phase Ib/II dose‐optimization study assessed itacitinib, a selective JAK1 inhibitor, combined with nab‐paclitaxel plus gemcitabine in adults with treatment‐naïve advanced/metastatic disease (Part 1) or pancreatic adenocarcinoma (Parts 2/2A; NCT01858883). Starting doses (Part 1) were itacitinib 400 mg, nab‐paclitaxel 125 mg/m2, and gemcitabine 1,000 mg/m2. Additional dose levels incorporated were granulocyte colony‐stimulating factor, de‐escalations of itacitinib to 300 mg once daily (QD), nab‐paclitaxel to 100 mg/m2, and gemcitabine to 750 mg/m2. Results. Among 55 patients in Part 1, 6 developed seven hematologic dose‐limiting toxicities (Cycle 1). Itacitinib 300 mg plus nab‐paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 was tolerated and expanded in Part 2. Treatment discontinuation and grade 3/4 neutropenia rates prompted itacitinib de‐escalation to 200 mg QD in Part 2A. The most common grade 3/4 toxicities were fatigue and neutropenia. Partial responses occurred across all itacitinib doses and several tumor types (overall response rate, 24%). Conclusion. Itacitinib plus chemotherapy demonstrated acceptable safety and clinical activity in patients with advanced solid tumors including pancreatic cancers. This study was terminated early (sponsor's decision) based on negative phase III results for a JAK1/2 inhibitor in previously treated advanced pancreatic cancer.
Collapse
Affiliation(s)
- Gregory L Beatty
- Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Safi Shahda
- Hematology/Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA
| | - Thaddeus Beck
- Hematology/Oncology, Highlands Oncology Group, Fayetteville, Arkansas, USA
| | - Nikhil Uppal
- Department of Medicine, NYU Langone Arena Oncology, Lake Success, New York, USA
| | - Steven J Cohen
- Medical Oncology and Hematology Division, Jefferson Health/Abington Memorial Hospital, Abington, Pennsylvania, USA
| | - Ross Donehower
- Division of Medical Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
| | - Afshin Eli Gabayan
- Hematology/Oncology, Beverly Hills Cancer Center, Beverly Hills, California, USA
| | - Albert Assad
- Oncology Drug Development, Incyte Corporation, Wilmington, Delaware, USA
| | - Julie Switzky
- Clinical Research, Incyte Corporation, Wilmington, Delaware, USA
| | - Huiling Zhen
- Biostatistics, Incyte Corporation, Wilmington, Delaware, USA
| | - Daniel D Von Hoff
- Molecular Medicine Division, Translational Genomics Research Institute (TGen), Scottsdale, Arizona, USA
- Oncology, HonorHealth Clinical Research Institute, Phoenix, Arizona, USA
| |
Collapse
|
21
|
Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget 2018; 9:31709-31718. [PMID: 30167089 PMCID: PMC6114962 DOI: 10.18632/oncotarget.25854] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 07/12/2018] [Indexed: 11/25/2022] Open
Abstract
Phosphatidylinositol 3-kinase (PI3K) pathway activation is associated with resistance to paclitaxel in solid tumors. We assessed the safety and activity of alpelisib, an oral, selective PI3K p110α inhibitor, plus paclitaxel in patients with advanced solid tumors. This Phase Ib, multicenter, open-label, dose-finding study, with a planned dose-expansion phase of alpelisib once daily (QD) plus fixed-dose paclitaxel, recruited patients with advanced solid tumors. For the dose-finding phase, the primary objective was determination of maximum tolerated and/or recommended Phase II dose of alpelisib plus paclitaxel, and the secondary objectives included the assessment of safety for this combination. From March 2014 to August 2016, 19 patients with advanced solid tumors were treated with alpelisib QD (300 mg, n=6; 250 mg, n=4; 150 mg, n=9) plus paclitaxel (80 mg/m2, per standard of care). During dose finding, five of 12 (41.7%) evaluable patients for MTD determination experienced dose-limiting toxicities: alpelisib 300 mg, Grade 2 hyperglycemia (n=1); alpelisib 250 mg, Grade 2 hyperglycemia (n=1), Grade 4 hyperglycemia and Grade 3 acute kidney injury (n=1); and alpelisib 150 mg, Grade 2 hyperglycemia (n=1) and Grade 4 leukopenia (n=1). The MTD of alpelisib when administered with paclitaxel was 150 mg QD. Most frequent all-grade AEs were diarrhea (73.7%; Grade 3/4 10.5%) and hyperglycemia (57.9%; Grade 3/4 31.6%). The planned dose-expansion phase was not initiated. Alpelisib plus paclitaxel has a challenging safety profile in patients with advanced solid tumors. This study was closed following the completion of the dose-finding phase. Clinical trial registration: ClinicalTrials.gov NCT02051751.
Collapse
Affiliation(s)
- Jordi Rodon
- Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Centro Cellex, 08035, Barcelona, Spain
| | - Giuseppe Curigliano
- Division of Early Drug Development for Innovative Therapies, Department of Hematology and Oncology, University of Milano, Istituto Europeo di Oncologia, 20141, Milan, Italy
| | - Jean-Pierre Delord
- Clinical Research Unit, Institut Claudius Regaud, 31052, Toulouse, France
| | - Wael Harb
- Horizon Oncology Center, 47905, Lafayette, IN, USA
| | - Analia Azaro
- Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Centro Cellex, 08035, Barcelona, Spain
| | - Yu Han
- Novartis Pharmaceuticals Corporation, 07936, East Hanover, NJ, USA
| | - Celine Wilke
- Novartis Pharma AG, Postfach, CH-4002, Basel, Switzerland
| | | | - Dalila Sellami
- Novartis Pharmaceuticals Corporation, 07936, East Hanover, NJ, USA
| | - Thaddeus Beck
- Highlands Oncology Group, 72703, Fayetteville, AR, USA
| |
Collapse
|
22
|
Lindberg-Larsen V, Petersen PB, Jans Ø, Beck T, Kehlet H. Effect of pre-operative methylprednisolone on orthostatic hypotension during early mobilization after total hip arthroplasty. Acta Anaesthesiol Scand 2018; 62:882-892. [PMID: 29573263 DOI: 10.1111/aas.13108] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Revised: 02/13/2018] [Accepted: 02/17/2018] [Indexed: 12/14/2022]
Abstract
BACKGROUND Orthostatic hypotension (OH) and intolerance (OI) are common after total hip arthroplasty (THA) and may delay early mobilization. The pathology of OH and OI includes a dysregulated post-operative vasopressor response, by a hitherto unknown mechanism. We hypothesized that OI could be related to the inflammatory stress response which is inhibited by steroid administration. Consequently, this study evaluated the effect of a pre-operative high-dose methylprednisolone on OH and OI early after THA. METHODS Randomized, double-blind, placebo-controlled study in 59 patients undergoing elective unilateral THA with spinal anesthesia and a standardized multimodal analgesic regime. Patients were allocated (1 : 1) to pre-operative intravenous (IV) methylprednisolone (MP) 125 mg or isotonic saline (C). OH, OI and cardiovascular responses to sitting and standing were evaluated using a standardized mobilization protocol pre-operatively, 6, and 24 h after surgery. Systolic and diastolic arterial pressure and heart rate were measured non-invasively (Nexfin® ). The systemic inflammation was monitored by the C-reactive protein (CRP) response. RESULTS At 6 h post-operatively, 11 (38%) versus 11 (37%) patients had OH in group MP and group C, respectively (RR 1.02 (0.60 to 1.75; P = 1.00)), whereas OI was present in 9 (31%) versus 13 (43%) patients (RR 0.76 (0.42 to 1.36; P = 0.42)), respectively. At 24 h post-operatively, the prevalence of OH and OI did not differ between groups, though CRP levels were significantly reduced in group MP (P < 0.001). CONCLUSION Pre-operative administration of 125 mg methylprednisolone IV did not reduce OH or OI compared with placebo despite a reduced inflammatory response.
Collapse
Affiliation(s)
- V. Lindberg-Larsen
- Section for Surgical Pathophysiology 7621; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark
- The Lundbeck Foundation Centre for Fast-Track Hip and Knee Arthroplasty; Copenhagen Denmark
| | - P. B. Petersen
- Section for Surgical Pathophysiology 7621; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark
- The Lundbeck Foundation Centre for Fast-Track Hip and Knee Arthroplasty; Copenhagen Denmark
| | - Ø. Jans
- The Lundbeck Foundation Centre for Fast-Track Hip and Knee Arthroplasty; Copenhagen Denmark
| | - T. Beck
- Department of Orthopaedic Surgery; Copenhagen University Hospital, Bispebjerg and Frederiksberg; Copenhagen Denmark
| | - H. Kehlet
- Section for Surgical Pathophysiology 7621; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark
- The Lundbeck Foundation Centre for Fast-Track Hip and Knee Arthroplasty; Copenhagen Denmark
| |
Collapse
|
23
|
|
24
|
Gorbunova V, Beck T, Hofheinz R, Garcia-Alfonso P, Nechaeva M, Cubillo Gracian A, Mangel L, Elez E, Deming DA, Ramanathan RK, Torres A, Sullivan DM, Komarnitsky PB, Berlin J. Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.3543] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Vera Gorbunova
- N. N. Blokhin Cancer Research Center, Moscow, Russian Federation
| | | | - Ralf Hofheinz
- Klinikum Mannheim Tagestherapie – Zentrum, Mannheim, Germany
| | | | - Marina Nechaeva
- Arkhangelsk Regional Clinical Oncologic Dispensary, Arkhangelsk, Russia
| | | | - Laszlo Mangel
- Pecsi Tudomanyegyetem Klinikai Kozpont, Pecsi, Hungary
| | - Elena Elez
- Medical Oncology Department, Vall d’Hebron University Hospital; Vall d’Hebron Institute of Oncology (VHIO)., Barcelona, Spain
| | | | | | | | | | | | - Jordan Berlin
- Vanderbilt University Ingram Cancer Center, Nashville, TN
| |
Collapse
|
25
|
Pietralla N, Kremer C, Beck T, Witt W, Gayer U, von Neumann-Cosel P, Werner V. Shell Evolution and E2 Collectivity: New Spectroscopic Information. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201817802007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
New spectroscopic information on electric quadrupole collectivity has recently been obtained. We report on our identification of a coexisting deformed structure in the quasi-doubly closed-shell nucleus 96Zr from our measurement of a corresponding absolute E2 intraband transition strength in electron scattering reactions and its small mixing matrix element with the spherical ground state structure. The even-mass zirconium isotopes exhibit a first order quantum shape phase transition between neutron numbers 58 and 60. We have used photon scattering reactions for a first measurement of the E2 decay strength of the nuclear 1+ scissors mode. Evidence for its 2+ rotational excitation and its extraordinarily large rotational moment of inertia are presented.
Collapse
|
26
|
Beck T, Beller J, Pietralla N, Bhike M, Birkhan J, Derya V, Gayer U, Hennig A, Isaak J, Löher B, Ponomarev VY, Richter A, Romig C, Savran D, Scheck M, Tornow W, Werner V, Zilges A, Zweidinger M. E2 decay strength of the M1 scissors mode of ^{156}Gd and its first excited rotational state. Phys Rev Lett 2017; 118:212502. [PMID: 28598677 DOI: 10.1103/physrevlett.118.212502] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Indexed: 06/07/2023]
Abstract
The E2/M1 multipole mixing ratio δ_{1→2} of the 1_{sc}^{+}→2_{1}^{+} γ-ray decay in ^{156}Gd and hence the isovector E2 transition rate of the scissors mode of a well-deformed rotational nucleus has been measured for the first time. It has been obtained from the angular distribution of an artificial quasimonochromatic linearly polarized γ-ray beam of energy 3.07(6) MeV scattered inelastically off an isotopically highly enriched ^{156}Gd target. The data yield first direct support for the deformation dependence of effective proton and neutron quadrupole boson charges in the framework of algebraic nuclear models. First evidence for a low-lying J^{π}=2^{+} member of the rotational band of states on top of the 1^{+} band head is obtained, too, indicating a significant signature splitting in the K=1 scissors mode rotational band.
Collapse
Affiliation(s)
- T Beck
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| | - J Beller
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| | - N Pietralla
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| | - M Bhike
- Department of Physics, Duke University and Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708-0308, USA
| | - J Birkhan
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| | - V Derya
- Institut für Kernphysik, Universität zu Köln, Zülpicher Str. 77, D-50937 Köln, Germany
| | - U Gayer
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| | - A Hennig
- Institut für Kernphysik, Universität zu Köln, Zülpicher Str. 77, D-50937 Köln, Germany
| | - J Isaak
- ExtreMe Matter Institute EMMI and Research Division, GSI Helmholtzzentrum für Schwerionenforschung, Planckstr. 1, D-64291 Darmstadt, Germany
- Frankfurt Institute for Advanced Studies FIAS, Ruth-Moufang-Str. 1, D-60438 Frankfurt am Main, Germany
| | - B Löher
- ExtreMe Matter Institute EMMI and Research Division, GSI Helmholtzzentrum für Schwerionenforschung, Planckstr. 1, D-64291 Darmstadt, Germany
- Frankfurt Institute for Advanced Studies FIAS, Ruth-Moufang-Str. 1, D-60438 Frankfurt am Main, Germany
| | - V Yu Ponomarev
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| | - A Richter
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| | - C Romig
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| | - D Savran
- ExtreMe Matter Institute EMMI and Research Division, GSI Helmholtzzentrum für Schwerionenforschung, Planckstr. 1, D-64291 Darmstadt, Germany
- Frankfurt Institute for Advanced Studies FIAS, Ruth-Moufang-Str. 1, D-60438 Frankfurt am Main, Germany
| | - M Scheck
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
- School of Engineering and Computing, University of the West of Scotland, Paisley PA1 2BE, United Kingdom
- SUPA, Scottish Universities Physics Alliance, Glasgow G12 8QQ, United Kingdom
| | - W Tornow
- Department of Physics, Duke University and Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708-0308, USA
| | - V Werner
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| | - A Zilges
- Institut für Kernphysik, Universität zu Köln, Zülpicher Str. 77, D-50937 Köln, Germany
| | - M Zweidinger
- Institut für Kernphysik, TU Darmstadt, Schlossgartenstr. 9, D-64289 Darmstadt, Germany
| |
Collapse
|
27
|
Rottmann M, Burges A, Mahner S, Anthuber C, Beck T, Grab D, Schnelzer A, Kiechle M, Mayr D, Pölcher M, Schubert-Fritschle G, Engel J. Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes. J Cancer Res Clin Oncol 2017; 143:1833-1844. [DOI: 10.1007/s00432-017-2422-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2016] [Accepted: 04/11/2017] [Indexed: 12/26/2022]
|
28
|
Campone M, Gianni L, Cortes J, Beck T, Miller J, Chen P, Fandi A, Sachdev JC. Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.tps616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Mario Campone
- Cancer Institute of the West (ICO), Centre René Gauducheau, Medical Oncology Department, Saint-Herblain, France
| | - Luca Gianni
- Department of Medical Oncology, San Raffaele Scientific Institute, Milano, Italy
| | - Javier Cortes
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
29
|
Tzschaschel M, Löhberg C, Beck T, Brudler O, Rack B. TREAT CTC: Eine innovative Studie zur Eliminierung von zirkulierenden Tumorzellen (CTCs) beim frühen Mammakarzinom. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1580679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
30
|
Kenkel D, Wurnig M, Filli L, Ulbrich E, Runge V, Beck T, Boss A. Whole-Body Diffusion Imaging Applying Simultaneous Multi-Slice Excitation. ROFO-FORTSCHR RONTG 2016; 188:E1. [DOI: 10.1055/s-0035-1567082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- D. Kenkel
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| | - M. Wurnig
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| | - L. Filli
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| | - E. Ulbrich
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| | - V. Runge
- Department of Neuroradiology, University Hospital Zurich, Switzerland
| | - T. Beck
- Siemens Healthcare GmbH, Erlangen, Germany
| | - A. Boss
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| |
Collapse
|
31
|
Kenkel D, Wurnig MC, Filli L, Ulbrich EJ, Runge VM, Beck T, Boss A. Whole-Body Diffusion Imaging Applying Simultaneous Multi-Slice Excitation. ROFO-FORTSCHR RONTG 2016; 188:381-8. [PMID: 26815283 DOI: 10.1055/s-0035-1567032] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
PURPOSE The purpose of this study was to examine the feasibility of a fast protocol for whole-body diffusion-weighted imaging (WB-DWI) using a slice-accelerated echo-planar sequence, which, when using comparable image acquisition parameters, noticeably reduces measurement time compared to a conventional WB-DWI protocol. MATERIALS AND METHODS A single-shot echo-planar imaging sequence capable of simultaneous slice excitation and acquisition was optimized for WB-DWI on a 3 T MR scanner, with a comparable conventional WB-DWI protocol serving as the reference standard. Eight healthy individuals and one oncologic patient underwent WB-DWI. Quantitative analysis was carried out by measuring the apparent diffusion coefficient (ADC) and its coefficient of variation (CV) in different organs. Image quality was assessed qualitatively by two independent radiologists using a 4-point Likert scale. RESULTS Using our proposed protocol, the scan time of the WB-DWI measurement was reduced by up to 25.9 %. Both protocols, the slice-accelerated protocol and the conventional protocol, showed comparable image quality without statistically significant differences in the reader scores. Similarly, no significant differences of the ADC values of parenchymal organs were found, whereas ADC values of brain tissue were slightly higher in the slice-accelerated protocol. CONCLUSION It was demonstrated that slice-accelerated DWI can be applied to WB-DWI protocols with the potential to greatly reduce the required measurement time, thereby substantially increasing clinical applicability. KEY POINTS •Whole-body diffusion-weighted imaging (WB-DWI) using simultaneous multi-slice and blipped-CAIPIRINHA reduces the measurement time strongly without having a significant impact on image quality. •The reduction in measurement time might strongly contribute to the clinical applicability of WB-DWI. •However, further refinement of the slice-accelerated EPI sequence, and the WB-DWI protocol applying this sequence type seems necessary; and the value of such WB-DWI protocols for assessment of systemic oncological diseases needs to be investigated in further clinical studies.
Collapse
Affiliation(s)
- D Kenkel
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| | - M C Wurnig
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| | - L Filli
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| | - E J Ulbrich
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| | - V M Runge
- Department of Neuroradiology, University Hospital Zurich, Switzerland
| | - T Beck
- Siemens Healthcare GmbH, Erlangen, Germany
| | - A Boss
- Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland
| |
Collapse
|
32
|
Rabanser B, Mitmansgruber H, Smrekar U, Beck T, Niedermayr K, Eder J, Ellemunter H. WS09.4 The role of resilience in quality of life of adult patients with cystic fibrosis (CF). J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30055-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Romig C, Beck T, Beller J, Birkhan J, Endres A, Fritzsche M, Gayer U, Glorius J, Isaak J, Mertes L, Pai H, Pietralla N, Ries P, Savran D, Scheck M, Schnorrenberger L, Sonnabend K, Werner V, Zweidinger M. Direct Determination of Ground-State Transition Widths and Natural Level Widths with the Method of Relative Self Absorption. EPJ Web of Conferences 2015. [DOI: 10.1051/epjconf/20159301035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Trosseille C, Aubert D, Auger L, Bazzoli S, Beck T, Brunel P, Burillo M, Chollet C, Gazave J, Jasmin S, Maruenda P, Moreau I, Oudot G, Raimbourg J, Soullié G, Stemmler P, Zuber C. Overview of the ARGOS X-ray framing camera for Laser MegaJoule. Rev Sci Instrum 2014; 85:11D620. [PMID: 25430196 DOI: 10.1063/1.4891057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Commissariat à l'Énergie Atomique et aux Énergies Alternatives has developed the ARGOS X-ray framing camera to perform two-dimensional, high-timing resolution imaging of an imploding target on the French high-power laser facility Laser MegaJoule. The main features of this camera are: a microchannel plate gated X-ray detector, a spring-loaded CCD camera that maintains proximity focus in any orientation, and electronics packages that provide remotely-selectable high-voltages to modify the exposure-time of the camera. These components are integrated into an "air-box" that protects them from the harsh environmental conditions. A miniaturized X-ray generator is also part of the device for in situ self-testing purposes.
Collapse
Affiliation(s)
| | - D Aubert
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - L Auger
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - S Bazzoli
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - T Beck
- CEA, DEN, CADARACHE, F-13108 St Paul lez Durance, France
| | - P Brunel
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - M Burillo
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - C Chollet
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - J Gazave
- CEA, DAM, CESTA, F-33116 Le Barp, France
| | - S Jasmin
- CEA, DAM, DIF, F-91297 Arpajon, France
| | | | - I Moreau
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - G Oudot
- CEA, DAM, DIF, F-91297 Arpajon, France
| | | | - G Soullié
- CEA, DAM, DIF, F-91297 Arpajon, France
| | | | - C Zuber
- CEA, DAM, DIF, F-91297 Arpajon, France
| |
Collapse
|
35
|
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer JU, Kittel K, Mau C, Potenberg J, Schilling J, Just M, Weiss E, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kunz G, Kast K, von Minckwitz G, Nestle-Krämling C, Rezai M, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Kühn T, Khandan F, Möbus V, Solbach C, Tesch H, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Holms F, Müller T, Deuker JU, Schrader I, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer HU, Conrad B, Feisel-Schwickardi G, Eidtmann H, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Ober A, Fischer D, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann DM, Hanusch C, Rack B, Salat C, Sattler D, Tio J, von Abel E, Christensen B, Burkamp U, Köhne CH, Meinerz W, Graßhoff ST, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Huober J, Weder P, Steffens CC, Lemster S, Stefek A, Ruhland F, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Fehm T, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Schlag R. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372. [PMID: 25223482 DOI: 10.1093/annonc/mdu455] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses. PATIENTS AND METHODS Patients (n = 1948) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel (EC-T) with or without eight infusions of bevacizumab every 3 weeks before surgery. Patients without clinical response to EC ± Bevacizumab were randomized to 12 weekly cycles paclitaxel with or without everolimus 5 mg/day. To detect a hazard ratio (HR) of 0.75 (α = 0.05, β = 0.8) 379 events had to be observed in the bevacizumab arms. RESULTS With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1-3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. CONCLUSIONS Long-term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline-taxane-based chemotherapy or everolimus in addition to paclitaxel for nonearly responding patients. CLINICAL TRIAL NUMBER NCT 00567554, www.clinicaltrials.gov.
Collapse
Affiliation(s)
- G von Minckwitz
- Headquarter, German Breast Group, Neu-Isenburg; Department of Gynaecology and Obstetrics, University Hospital, Frankfurt.
| | - S Loibl
- Headquarter, German Breast Group, Neu-Isenburg
| | - M Untch
- Department of Gynaecology and Obstetrics, Klinikum Berlin-Buch, Berlin
| | - H Eidtmann
- Department of Gynaecology and Obstetrics, University Hospital, Kiel
| | - M Rezai
- Breast Center, Luisenkrankenhaus, Düsseldorf
| | - P A Fasching
- Department of Gynaecology and Obstetrics, University Hospital, Erlangen
| | - H Tesch
- Department of Medical Oncology, Chop GmbH, Frankfurt
| | - H Eggemann
- Department of Gynaecology and Obstetrics, University Hospital, Magdeburg
| | - I Schrader
- Department of Gynaecology and Obstetrics, Henriettenstiftung, Hannover
| | - K Kittel
- Department of Gynaecology and Obstetrics, Praxisklinik, Berlin
| | - C Hanusch
- Department of Gynaecology and Obstetrics, Rot-Kreuz-Klinikum, München
| | - J Huober
- Department of Gynaecology and Obstetrics, University Hospital, Ulm
| | - C Solbach
- Department of Gynaecology and Obstetrics, University Hospital, Frankfurt
| | - C Jackisch
- Department of Gynaecology and Obstetrics, Sana-Klinikum, Offenbach
| | - G Kunz
- Department of Gynaecology and Obstetrics, St Johannes Hospital, Dortmund
| | - J U Blohmer
- Department of Gynaecology and Obstetrics, St Gertrauden-Hospital, Berlin
| | - M Hauschild
- Department of Gynaecology and Obstetrics, Hospital, Rheinfelden
| | - T Fehm
- Department of Gynaecology and Obstetrics, University Hospital, Tübingen
| | | | - B Gerber
- Department of Gynaecology and Obstetrics, University Hospital, Rostock, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Berger J, Beck T, Mital P, Sukhwani M, Kelley J, Krivak T, Orwig K. Platinum and taxane-induced ovarian damage in a mouse model: mechanisms and implications for gonadoprotection. Fertil Steril 2014. [DOI: 10.1016/j.fertnstert.2014.07.511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Luger TJ, Stadler A, Gorur P, Terlevic R, Neuner J, Simonsen O, Sansone P, Toferer E, Luger MF, Winter E, Beck T. Medical preparedness, incidents, and group dynamics during the analog MARS2013 mission. Astrobiology 2014; 14:438-450. [PMID: 24823803 DOI: 10.1089/ast.2013.1128] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Participants on spaceflights and international scientific analog Mars missions can encounter medical incidents (accidents, illnesses) and psychological issues (e.g., stress, group interaction, sleep disturbance, emotions). The aim of this study was to examine these parameters in a field crew living in a desert environment similar to Mars (Group 1) and in Mission Support Center (MSC) personnel on "Earth" (Group 2) during a 4-week mission. Of the 107 medical interventions in the field, 73 mainly minor incidents together with four near accidents and 29 medical checkup interventions were recorded. Of the 32 medical interventions, medical treatments for 23 incidents of minor severity were necessary in Group 2. Injuries (Group 1: 1.4/100 h, Group 2: 0.1/100 h) were significantly increased in the field, and illnesses (Group 1: 0.3/100 h, Group 2: 3.0/100 h) in the MSC personnel. Causes of accidents and illnesses are described. Psychological results show that emotions and stress remained stable in both groups. Sympathy, social competence, teamwork, and leadership showed high scores. These scores were lower on "Earth" but significantly increased in the last weeks. The Sahara's nighttime coldness was reflected in an increased wake-up frequency, and a longer sleeping time peaked in the third week, probably as a result of overfatigue. MARS2013 was a successful mission with highly motivated participants and minor medical incidents. For future analog missions and possibly long-distance open-space missions, some recommendations in terms of medical and psychological preparedness are made to reduce risks for field crew members and MSC personnel.
Collapse
Affiliation(s)
- T J Luger
- 1 Department of Anesthesiology and Critical Care Medicine, Innsbruck Medical University , Innsbruck, Austria
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Beck T. Position Paper on the Necessity for Inpatient Primary Treatment of Breast Cancer. Geburtshilfe Frauenheilkd 2014; 73:1005-1006. [PMID: 24771888 DOI: 10.1055/s-0033-1350949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- T Beck
- Klinik für Gynäkologie und Geburtshilfe, RoMed Klinikum Rosenheim, Rosenheim
| |
Collapse
|
39
|
Besson J, Beck T, Wiesbeck G, Hämmig R, Kuntz A, Abid S, Stohler R. Opioid maintenance therapy in Switzerland: an overview of the Swiss IMPROVE study. Swiss Med Wkly 2014; 144:w13933. [PMID: 24706398 DOI: 10.4414/smw.2014.13933] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS Switzerland's drug policy model has always been unique and progressive, but there is a need to reassess this system in a rapidly changing world. The IMPROVE study was conducted to gain understanding of the attitudes and beliefs towards opioid maintenance therapy (OMT) in Switzerland with regards to quality and access to treatment. To obtain a "real-world" view on OMT, the study approached its goals from two different angles: from the perspectives of the OMT patients and of the physicians who treat patients with maintenance therapy. The IMPROVE study collected a large body of data on OMT in Switzerland. This paper presents a small subset of the dataset, focusing on the research design and methodology, the profile of the participants and the responses to several key questions addressed by the questionnaires. METHODS IMPROVE was an observational, questionnaire-based cross-sectional study on OMT conducted in Switzerland. Respondents consisted of OMT patients and treating physicians from various regions of the country. Data were collected using questionnaires in German and French. Physicians were interviewed by phone with a computer-based questionnaire. Patients self-completed a paper-based questionnaire at the physicians' offices or OMT treatment centres. RESULTS A total of 200 physicians and 207 patients participated in the study. Liquid methadone and methadone tablets or capsules were the medications most commonly prescribed by physicians (60% and 20% of patient load, respectively) whereas buprenorphine use was less frequent. Patients (88%) and physicians (83%) were generally satisfied with the OMT currently offered. The current political framework and lack of training or information were cited as determining factors that deter physicians from engaging in OMT. About 31% of OMT physicians interviewed were ≥60 years old, indicating an ageing population. Diversion and misuse were considered a significant problem in Switzerland by 45% of the physicians. CONCLUSION The subset of IMPROVE data presented gives a present-day, real-life overview of the OMT landscape in Switzerland. It represents a valuable resource for policy makers, key opinion leaders and drug addiction researchers and will be a useful basis for improving the current Swiss OMT model.
Collapse
Affiliation(s)
- J Besson
- CHUV, Rue St-Martin 7, 1003, Lausanne, SWITZERLAND;
| | | | | | | | | | | | | |
Collapse
|
40
|
Quoix E, Sequist L, Nemunaitis J, Beck T, Jaskiewicz P, Oster JP, Scherpereel A, Juhász E, Mark Z, Alvarez R, Waqar S, Potz J, Vrindavanam N, Melnyk A, Ross H, Limacher JM. TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study. J Immunother Cancer 2014. [PMCID: PMC4288318 DOI: 10.1186/2051-1426-2-s3-o12] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
41
|
Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31:4349-57. [PMID: 24145346 PMCID: PMC4881367 DOI: 10.1200/jco.2012.47.9626] [Citation(s) in RCA: 293] [Impact Index Per Article: 26.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. Eligible patients received maintenance until disease progression: pemetrexed plus bevacizumab (for the PemCBev group) or bevacizumab (for the PacCBev group). The primary end point of this superiority study was overall survival (OS). RESULTS Patients were randomly assigned to PemCBev (n = 472) or PacCBev (n = 467). For PemCBev versus PacCBev, OS hazard ratio (HR) was 1.00 (median OS, 12.6 v 13.4 months; P = .949); progression-free survival (PFS) HR was 0.83 (median PFS, 6.0 v 5.6 months; P = .012); overall response rate was 34.1% versus 33.0%; and disease control rate was 65.9% versus 69.8%. Significantly more study drug-related grade 3 or 4 anemia (14.5% v 2.7%), thrombocytopenia (23.3% v 5.6%), and fatigue (10.9% v 5.0%) occurred with PemCBev; significantly more grade 3 or 4 neutropenia (40.6% v 25.8%), febrile neutropenia (4.1% v 1.4%), sensory neuropathy (4.1% v 0%), and alopecia (grade 1 or 2; 36.8% v 6.6%) occurred with PacCBev. CONCLUSION OS did not improve with the PemCBev regimen compared with the PacCBev regimen, although PFS was significantly improved with PemCBev. Toxicity profiles differed; both regimens demonstrated tolerability.
Collapse
Affiliation(s)
- Jyoti D. Patel
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Mark A. Socinski
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Edward B. Garon
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Craig H. Reynolds
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - David R. Spigel
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Mark R. Olsen
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Robert C. Hermann
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Robert M. Jotte
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Thaddeus Beck
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Donald A. Richards
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Susan C. Guba
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Jingyi Liu
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Bente Frimodt-Moller
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - William J. John
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Coleman K. Obasaju
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Eduardo J. Pennella
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Philip Bonomi
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| | - Ramaswamy Govindan
- Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO
| |
Collapse
|
42
|
Taylor S, Beck T, Krivak T, Zorn K, Kelley J, Edwards R. Successful oxaliplatin salvage for recurrent ovarian cancer after carboplatin/cisplatin allergy. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
43
|
Schusser S, Smrekar U, Mitmansgruber H, Beck T, Hohenberger C, Eder J, Niedermayr K, Ellemunter H. 311 Do quality of life responses signal severe loss of lung function? J Cyst Fibros 2013. [DOI: 10.1016/s1569-1993(13)60452-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
44
|
Abstract
Pulmonary neuroendocrine tumors (NET) are rare, and very few published reports have described the long-term treatment of patients with this disease. Current treatment options for patients with metastatic well-differentiated pulmonary NET are limited. This case report details the long-term treatment of a 62-year-old female patient with well-differentiated pulmonary NET and multiple liver metastases. The heavily pretreated patient achieved radiographic stability in measurable disease, improvement in nonmeasurable disease, and symptomatic improvement over 3 years while receiving the combination of everolimus and octreotide long-acting repeatable (LAR). Treatment was well tolerated without mucositis, rash, or pneumonitis. This case report suggests that the combination of everolimus and octreotide LAR may be a novel treatment option for heavily pretreated patients with metastatic well-differentiated pulmonary NET, but these findings require further analysis in clinical trials.
Collapse
|
45
|
Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CGJ, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013; 49:1825-35. [PMID: 23490655 DOI: 10.1016/j.ejca.2013.01.007] [Citation(s) in RCA: 122] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2012] [Revised: 01/03/2013] [Accepted: 01/09/2013] [Indexed: 11/25/2022]
Abstract
AIM Final 10-year analysis of the prospective randomised Chemo-N0 trial is presented. Based on the Chemo-N0 interim results and an European Organisation for Research and Treatment of Cancer (EORTC) pooled analysis (n=8377), American Society of Clinical Oncology (ASCO) and Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) guidelines recommend invasion and metastasis markers urokinase-type plasminogen activator (uPA)/plasminogen activator inhibitor-1 (PAI-1) for risk assessment and treatment decision in node-negative (N0) breast cancer (BC). METHODS The final Chemo-N0 trial analysis (recruitment 1993-1998; n=647; 12 centres) comprises 113 (5-167) months of median follow-up. Patients with low-uPA and PAI-1 tumour tissue levels (n=283) were observed. External quality assurance guaranteed uPA/PAI-1 enzyme-linked immunosorbent assay (ELISA) standardisation. Of 364 high uPA and/or PAI-1 patients, 242 agreed to randomisation for CMF chemotherapy (n=117) versus observation (n=125). RESULTS Actuarial 10-year recurrence rate (without any adjuvant systemic therapy) for high-uPA/PAI-1 observation group patients (randomised and non-randomised) was 23.0%, in contrast to only 12.9% for low-uPA/PAI-1 patients (plog-rank=0.011). High-risk patients randomised to cyclophosphamide-methotrexate-5-fluorouracil (CMF) therapy had a 26.0% lower estimated probability of disease recurrence than those randomised for observation (intention-to-treat (ITT)-analysis: hazard ratio (HR) 0.74 (0.44-1.27); plog-rank=0.28). Per-protocol analysis demonstrated significant treatment benefit: HR 0.48 (0.26-0.88), p=0.019, disease-free survival (DFS) Cox regression, adjusted for tumour stage and grade. CONCLUSIONS Chemo-N0 is the first prospective biomarker-based therapy trial in early BC defining patients reaching good long-term DFS without adjuvant systemic therapy. Using a standardised uPA/PAI-1 ELISA, almost half of N0-patients could be spared chemotherapy, while high-risk patients benefit from adjuvant chemotherapy. These 10-year results validate the long-term prognostic impact of uPA/PAI-1 and the benefit from adjuvant chemotherapy in the high-uPA/PAI-1 group at highest level of evidence. They thus support the guideline-based routine use of uPA/PAI-1 for risk-adapted individualised therapy decisions in N0 breast cancer.
Collapse
Affiliation(s)
- N Harbeck
- Brustzentrum, Frauenklinik Maistrasse, Universitaet München, 80337 Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Hepp P, Tesch H, Forstbauer H, Rezai M, Beck T, Schrader I, Kleine-Tebbe A, Hucke J, Finas D, Soeling U, Zahm DM, Weiss E, Beckmann MW, Janni W, Rack B. Abstract P2-10-25: Prognostic value of relative change in tumor marker CA 27.29 in early stage breast cancer – The SUCCESS trial. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-10-25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: MUC1 based tumor markers like CA27.29 (TM) in breast cancer are routinely used in metastatic disease as early marker for treatment efficacy. However, in early stage disease data is sparse. In this analysis, we looked at the impact of individual change in CA27.29 on prognosis instead of using a threshold.
Methods: The SUCCESS Trial compares FEC-docetaxel (Doc) vs. FEC-Doc-Gemcitabine (Doc-G) regime and two vs. five year treatment with Zoledronat in 3754 patients (pts) with primary breast cancer (N+ or high risk N0). We measured CA27.29 after surgery but before chemotherapy (CHT) as baseline and compared it to CA27.29 levels 2 years thereafter with the ST AIA-PACK Ca27.29 reagent using MUC-1 for AIA-600II (Tosoh Bioscience, Tessenderlo, Belgium).
Results: CA27.29 data is available of 2,015 pts. 119 pts (5.9%) had TM over the threshold of 32U/ml before CHT and 56 (2.8%) 2years thereafter. To examine the relative change of tumor marker, pts were divided into 3 groups:
increase: change >=5 U/ml; stable: change <±5U/ml; decrease: change > = −5 U/ml.
123 (6.1%) pts had increasing (>=5 U/ml), 1419 (70.4%) had stable, 473 (23.5%) had decreasing TM levels from before CHT to 2 years thereafter. The majority of pts with increasing TM (86 pts; 69.9%) had levels below the usual threshold of 32U/ml at all times. Patients with an increase >=5 U/ml had an 81% increased risk for recurrence (HR = 1.810 [CI: 1.111–2.948]) and reduced overall survival (HR = 1.020 [CI: 1.004–1.037]). In the multivariate analysis taking into account tumor size, nodal status, grading, age, hormonal and HER2/neu receptor status increasing CA27.29 levels were an independent prognostic marker.
Conclusions: An increase of the tumor marker CA27.29 2 years after CHT compared to pre-chemotherapy baseline was associated with a worse prognosis. By using this approach, more patients at risk for recurrence were detected than with the standard threshold approach. Therefore, the use of relative change could help to identify more patients at risk for relapse who might benefit from an intensified follow up.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-10-25.
Collapse
Affiliation(s)
- P Hepp
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - H Tesch
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - H Forstbauer
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - M Rezai
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - T Beck
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - I Schrader
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - A Kleine-Tebbe
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - J Hucke
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - D Finas
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - U Soeling
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - D-M Zahm
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - E Weiss
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - MW Beckmann
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - W Janni
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| | - B Rack
- University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich
| |
Collapse
|
47
|
Beck T, Trunova O, Herzog R, Singheiser L. TBCs for Gas Turbines under Thermomechanical Loadings: Failure Behaviour and Life Prediction. EPJ Web of Conferences 2012. [DOI: 10.1051/epjconf/20123302001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
48
|
Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA. Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer. Clin Breast Cancer 2012; 12:322-30. [DOI: 10.1016/j.clbc.2012.07.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2011] [Revised: 06/26/2012] [Accepted: 07/09/2012] [Indexed: 10/27/2022]
|
49
|
Prickaerts P, Adriaens M, Chan-Seng-Yue M, Beck T, Koritzinsky M, Voncken W, Wouters B. 347 NOVEL MECHANISMS OF GENE REGULATION BY HYPOXIA. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70303-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
50
|
Jaeger BAS, Rack B, Jueckstock J, Salmen J, Ortmann U, Lorenz R, Rezai M, Beck T, Schneeweiss A, Zwingers T, Beckmann MW, Friese K, Janni W. P4-07-06: Correlation of Two Analytical Methods for Circulating Tumor Cells in Peripheral Blood of Patients with Primary Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-07-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
While the evidence for circulating tumor cells (CTCs) as a prognostic marker in metastatic breast cancer has been well established, there is still a lack of data in primary disease. In the SUCCESS A trial two different techniques for the detection of CTCs in early breast cancer were prospectively evaluated.
Material and Methods: SUCCESS A compared FEC-Docetaxel vs. FEC-Docetaxel-Gemcitabine and 5 vs. 2 years of treatment with zoledronic acid in primary breast cancer patients and node positive or high-risk node negative disease. Two different techniques to detect CTCs were prospectively evaluated in two consecutive, but comparable subgroups of the whole study population.
In 3515 samples the CellSearch® System (Veridex, Warren, USA) was used for CTC detection. Immunomagnetic enrichment with an EPCAM-antibody was followed by labeling with monoclonal antibodies specific for cytokeratin (8, 18, 19) and leukocytes (CD45). 2165 samples were evaluated with a manual immunocytochemistry (MICC) protocol. Cytospins were prepared after mononuclear cell enrichment based on Oncoquick® centrifugation (greiner bio-one, Frickenhausen, Germany). Staining was performed with the monoclonal pancytokeratin antibody A45-B/B3 (Micromet, Munich, Germany) and the APAAP technique. Conventional light field microscopy (Axiophot; Zeiss, Oberkochen, Germany) was used for the detection of stained cells.
For both methods, the cut-off value for positivity was ≥ 1 CTC. All events were evaluated by two independent observers.
Results: CTCs were examined in a total number of 3243 patients before and after chemotherapy (CHT). The two subgroups evaluated with one or the other method were well-balanced regarding clinical parameters as tumor size, grading, lymph node-status, hormone receptors and Her2. Furthermore there was no significant correlation between the CTC positivity and one of these clinical parameters using CellSearch or the MICC, respectively (p > 0,05 using the chi square test each time).
Before adjuvant CHT 21. 3% (424 out of 1994) and 21.1 % (264 out of 1249) of the patients were found positive for CTCs using CellSearch® or the MICC respectively, with a mean CTC level of 5.9 (range: 1 to 827) and 3.1 (range: 1 to 256).
Immediately after CHT 21.9% (333 out of 1521) and 16.5% (151 out of 916) of the patients were positive for CTCs using CellSearch® or the MICC. The mean CTC level decreased to 3.0 (range: 1 to 124) and 2.1 (range: 1 to 23) in both analytical methods.
Using CellSearch® there was a significant correlation between the presence of CTCs before CHT and disease progression (p = 0.0044), as well as survival (p = 0.0001), whereas the MICC did not predict any of these (p = 0.3143 and p = 0.0801 respectively; the chi-square test was used each time).
Conclusion: We found comparable prevalence of CTCs before and after adjuvant chemotherapy both with the CellSearch® System or the MICC. However, prognostic relevance could only be shown for CTCs detected with the CellSearch® System. This may be attributed to the high standardization and reproducibility of the automated system, as well as the additional CD45 counterstaining. According to our findings, the FDA approved CellSearch® System should be used as gold standard for CTC detection in future clinical trials.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-06.
Collapse
Affiliation(s)
- BAS Jaeger
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - B Rack
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - J Jueckstock
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - J Salmen
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - U Ortmann
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - R Lorenz
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - M Rezai
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - T Beck
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - A Schneeweiss
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - T Zwingers
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - MW Beckmann
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - K Friese
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| | - W Janni
- 1Klinikum der Ludwig-Maximilians-Universitaet -Campus Innenstadt, Munich, Germany; Heinrich Heine-Universitaet, Duesseldorf, Germany; Gemeinschaftspraxis Lorenz-HeckerWesche, Braunschweig, Germany; Luisenkrankenhaus, Duesseldorf, Germany; RoMed Klinikum Rosenheim, Rosenheim, Germany; University Hospital Heidelberg, Heidelberg, Germany; Estimate, Augsburg, Germany; Frauenklinik der Universitaet Erlangen, Erlangen, Germany
| |
Collapse
|